Patent ID: 7563774
Filing Date: 2009-07-21
Classification: A61K

Abstract:
1. A pharmaceutical composition comprising a pharmaceutically effective amount of at least one insulin secretagogue and a pharmaceutically effective amount of at least one FBPase inhibitor, wherein said insulin secretagogue is selected from a group consisting of sulfonylurea antidiabetic agents and non-sulfonylurea antidiabetic agents, and the FBPase inhibitor is selected from the group consisting of formulae I and IA and pharmaceutically acceptable prodrugs and salts thereof, wherein formulae I and IA are as follows: wherein in vivo or in vitro compounds of formulae I and IA are converted to M-PO 3 2− , which inhibits FBPase, and wherein: Y is independently selected from —O— and —NR wherein a) V is selected from the group of aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkynyl and 1-alkenyl; or b) V c) Z′ is selected from the group of —OH, —OC(O)R R R each R R n is an integer from 1 to 3; R each R each R R R each R R M is selected from the group consisting of wherein: U wherein: B D Q with the provisos that: and Q 5 is —C═;